MedTrace Logo

Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19)

NCT04448769 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2006

Last updated 2020-08-19

No results posted yet for this study

Summary

In order to inform the public decision on the containment strategy and knowledge of the intensity of the epidemic during post-containment, estimates of the share of the population infected with the SARS-CoV-2 virus responsible for COVID-19 disease at the territorial level are needed as soon as possible. The aim of the study is to estimate the prevalence of positive anti-SARS-CoV-2 serologies by detection of IgT-total antibodies (IgM/IgA/IgG) in the general population of the Grand Nancy Metropolitan area.

A study of seroprevalence and symptom collection, or absence of symptoms, on a cluster (household) sample of the Grand Nancy Metropolitan population randomly selected will be conducted.

The target population consists of all the inhabitants of the Grand Nancy Metropolitan area, from which a sample is drawn from the electoral lists (households) in a random manner to ensure representativeness. In order to ultimately include 2000 people in the study

Conditions

  • Coronavirus Infection
  • Prevalence

Interventions

BIOLOGICAL

Anti-SARS-CoV-2 IgT seropositivity

Each inhabitant who agrees to participate will have to : * sign the consent form after receiving complete information * complete a questionnaire exploring sociodemographic (gender, age, professional activity...), medical (anthropometric measures, health problems, smoking...), potential contacts with COVID-19 and symptoms. * take a blood sample for the dermination of anti-SARS-CoV-2 IgT seropositivity of the individuals tested in the population of the Grand Nancy Metropolitan area (GNM).

Sponsors & Collaborators

  • University of Lorraine

    collaborator OTHER

  • Métropole du Grand Nancy

    collaborator UNKNOWN

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Evelyne Schvoerer · CHRU Nancy

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-26
Primary Completion
2020-07-24
Completion
2020-07-24

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04448769 on ClinicalTrials.gov